Related Experiment Video
Updated: Aug 2, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C
S Kharbanda1, Z M Yuan, N Taneja
1Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
Abstract:
The present studies have examined the effects of mitomycin C (MMC), a genotoxic alkylating agent, on the activation of Src-like protein tyrosine kinases in HL-60 myeloid leukemia cells. The results demonstrate no detectable induction of p59fyn or pp60c-src activity. The response of HL-60 cells to MMC however was associated with rapid activation of p56/p53lyn. Similar findings were obtained with other alkylating agents such as nitrogen mustard and cis-platinum. Activation of p56/p53lyn was associated with increased autophosphorylation on tyrosine and sensitivity to the tyrosine kinase inhibitors herbimycin A and genistein. Studies with a glutathione S-transferase-Lyn fusion protein were performed to explore the potential significance of p56/p53lyn activation. Analysis of the adsorbates demonstrates interaction of Lyn with the cell cycle regulatory protein, p34cdc2. Coimmunoprecipitation studies further confirmed the association of p56/p53lyn and p34cdc2 in MMC-treated cells. We also demonstrate that p34cdc2 undergoes increased phosphorylation on tyrosine following MMC exposure and that p56/p53lyn phosphorylates the Tyr-15 site of p34cdc2 in vitro. These findings indicate that the cellular response to MMC includes activation of p56/p53lyn and that this event may contribute to signals transduced by the DNA damage-dependent mitotic checkpoint.
Insights
Mitomycin C (MMC) activates p56/p53lyn tyrosine kinase in leukemia cells, unlike other kinases. This activation is linked to the cell cycle protein p34cdc2, potentially impacting DNA damage response.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Genotoxic agents like mitomycin C (MMC) can induce cellular responses.
- Protein tyrosine kinases play crucial roles in cell signaling pathways.
- The activation of specific kinases in response to DNA damage is not fully understood.
Purpose of the Study:
- To investigate the effects of mitomycin C (MMC) on Src-like protein tyrosine kinases in HL-60 myeloid leukemia cells.
- To determine the role of p56/p53lyn activation in cellular response to alkylating agents.
- To elucidate the interaction between activated p56/p53lyn and cell cycle regulatory proteins.
Main Methods:
- Treatment of HL-60 cells with mitomycin C and other alkylating agents.
- Assessing the activity of protein tyrosine kinases (p59fyn, pp60c-src, p56/p53lyn) using biochemical assays.
- Utilizing tyrosine kinase inhibitors (herbimycin A, genistein) to study kinase sensitivity.
- Employing glutathione S-transferase (GST)-Lyn fusion protein for interaction studies.
- Performing coimmunoprecipitation and in vitro kinase assays to confirm protein associations and phosphorylation sites.
Main Results:
- Mitomycin C did not induce p59fyn or pp60c-src activity but rapidly activated p56/p53lyn.
- Activation of p56/p53lyn involved increased autophosphorylation and sensitivity to kinase inhibitors.
- p56/p53lyn was found to interact with the cell cycle protein p34cdc2.
- p34cdc2 showed increased tyrosine phosphorylation upon MMC exposure, with p56/p53lyn phosphorylating Tyr-15 in vitro.
Conclusions:
- The cellular response to mitomycin C involves the activation of p56/p53lyn.
- p56/p53lyn activation and its interaction with p34cdc2 may be involved in the DNA damage-dependent mitotic checkpoint signaling.
- These findings provide insights into the molecular mechanisms of DNA damage response pathways in leukemia cells.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle

